Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 17/20 | 0.42 |
| ▸ | SCN1A | P35498 | 15/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21773267 | 1.00 | SCN8A (0.42) | SCN8ASCN1AKEAP1NFE2L2MMP9 | |
| SCHEMBL21773268 | 1.00 | SCN8A (0.42) | SCN8ASCN1AKEAP1NFE2L2MMP9 | |
| SCHEMBL21789154 | 0.91 | SCN8A (0.40) | SCN8ASCN1A | |
| SCHEMBL30845699 | 0.91 | SCN8A (0.40) | SCN8ASCN1A | |
| SCHEMBL21773229 | 0.87 | SCN8A (0.47) | SCN8ASCN1A | |
| SCHEMBL21773225 | 0.87 | SCN8A (0.47) | SCN8ASCN1A | |
| SCHEMBL21773278 | 0.86 | MMP9 (0.36) | SCN8ASCN1AKEAP1NFE2L2MMP9 | |
| SCHEMBL21773280 | 0.86 | MMP9 (0.36) | SCN8ASCN1AKEAP1NFE2L2MMP9 | |
| SCHEMBL21773285 | 0.86 | MMP9 (0.36) | SCN8ASCN1AKEAP1NFE2L2MMP9 | |
| SCHEMBL21789506 | 0.81 | SCN8A (0.43) | SCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885KEAP1 2773/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885KEAP1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.